EMA recommends approval of Revolution's pancreatic cancer drug
15/10/2026 14:47
EMA recommends approval of Revolution's pancreatic cancer drug Oct 15 (Reuters) - The European Medicines Agency on Thursday recommended approval of Revolution Medicines' RVMD.O pancreatic cancer drug Rasonque in the EU.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Vijay Kishore)
Recent news on Revolution Medicines
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
Brief: CHMP Recommends Granting Marketing Authorisation For Rasonque For Metastatic Pancreatic Cancer In EU
Revolution Medicines wins EU committee backing for pancreatic cancer treatment (updated)
EMA recommends approval of Revolution's pancreatic cancer drug
Revolution Medicines falls on pancreatic cancer drug data concerns